ADRX

ADARx Pharmaceuticals Inc

17.65

Oct 16 • 3:59 PM ET -0.05 (-0.28%)

17.83

Aftermarket • 7:30 PM ET +0.18 (1.02%)

Healthcare Biotechnology USA Small NASD

Held by: VTI VXF VTWO TMED TDNA TSEE VTWG VTWV

Scroll to Statements

Index	-
Market Cap	1.96B
Enterprise Value	1.89B
Income	-
Sales	-
Book/sh	-2.35
Cash/sh	3.85
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	-
IPO	Sep 25, 2026

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	-
P/C	4.58
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	12.98
Current Ratio	12.98
Debt/Eq	0.06
LT Debt/Eq	0.05
Option/Short	No / Yes

EPS (ttm)	-
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	- -
Sales past 3/5Y	- -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	-
Sales Q/Q	-
Earnings	-
EPS/Sales Surpr.	- -

Insider Own	59.08%
Insider Trans	8.56%
Inst Own	-
Inst Trans	20.08%
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-4.94%
SMA50	-4.94%
SMA200	-4.94%
Trades

Shs Outstand	106.80M
Shs Float	45.36M
Short Float	2.56%
Short Ratio	1.22
Short Interest	1.16M
52W High	23.21 -23.96%
52W Low	16.64 6.07%
Volatility	6.08% -
ATR (14)	1.76
RSI (14)	38.51
Beta	-
Rel Volume	0.26
Avg Volume	953.63K
Volume	247,130

Perf Week	-0.73%
Perf Month	-
Perf Quarter	-
Perf Half Y	-
Perf YTD	-20.14%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	-
Target Price	-
Prev Close	17.70
Price	17.65
Change %	-0.28%

Oct-01-26 04:15PM

ADARx Pharmaceuticals Announces the Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares Granted in Its Initial Public Offering

(GlobeNewswire) -6.60%

ADARx Pharmaceuticals, Inc. is a late-clinical-stage biotechnology company. It focuses on developing next-generation small interfering RNA (siRNA) therapeutics for diseases with significant unmet medical needs. The company was founded by Zhen Li in December 2019 and is headquartered in San Diego, CA.

Co-FounderDr. Zhen Li Ph.D.

Chief Scientific OfficerDr. Robert A. MacLeod Ph.D.

CFO & Chief Business OfficerMr. Ryan Fisk M.B.A.

Ph.D.Dr. Christopher Claeboe M.B.A.

Chief Technology OfficerDr. Rui Zhu Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Chimovits Erez	Director	Sep 28 '26	Buy	17.00	61,516	1,045,772	9,292,025	Sep 30 05:29 PM
GORDON CARL L	Director	Sep 28 '26	Buy	17.00	950,000	16,150,000	14,325,529	Sep 30 05:25 PM
ORBIMED ADVISORS LLC	Director	Sep 28 '26	Buy	17.00	950,000	16,150,000	14,325,529	Sep 30 05:23 PM
SR ONE CAPITAL MANAGEMENT, LLC	10% Owner	Sep 28 '26	Buy	17.00	1,600,000	27,200,000	5,554,094	Sep 29 09:45 PM
George Simeon	Director	Sep 28 '26	Buy	17.00	1,600,000	27,200,000	5,554,094	Sep 29 09:43 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ADRX

ADARx Pharmaceuticals Inc

Upgrade your Finviz experience